Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Simple Summary This paper deals with Belantamab mafodotin, a novel anti-BCMA antibody-
drug conjugate licensed by regulatory agencies for the treatment of anti-CD38-refractory …

Simple Summary Patients with multiple myeloma (MM) who become refractory to three or
more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them …

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma
(MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy …

Background Patients with relapsed/refractory multiple myeloma (RRMM) have a high unmet
treatment need. Belantamab mafodotin (belamaf), a first‐in‐class, B‐cell maturation antigen …

Secondary antibody deficiency (SAD) is a subtype of secondary immunodeficiency
characterized by low serum antibody concentrations (hypogammaglobulinemia) or poor …

Background Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of
multiple myeloma (MM) and light chain amyloidosis at an intravenous dosage of 16 mg/kg or …

Simple Summary Refractoriness to the five main myeloma treatments, including
lenalidomide, pomalidomide, bortezomib, carfilzomib, and either daratumumab or …

In myeloma patients, high levels of soluble BCMA (sBCMA) can limit the efficacy of BCMA-
directed therapies. Belantamab-mafodotin is a BCMA antibody-drug conjugate and shows …

Objectives The aim of this noninterventional, retrospective ALFA study was to describe
belantamab mafodotin effectiveness and safety in patients with relapsed/refractory multiple …